Original report
The U.S. Food and Drug Administration granted accelerated approval to Forzinity (elamipretide) injection on September 19, 2025. FDA identifies it as the first approved treatment for Barth syndrome and indicates it to improve muscle strength in adults and pediatric patients weighing at least 30 kilograms. Barth syndrome is a rare inherited condition associated with muscle weakness and other serious health problems. Forzinity is a mitochondria-targeting peptide medicine. Its approval under FDA’s accelerated approval pathway is specific to this condition and eligible weight group; it does not make elamipretide an approved treatment for unrelated conditions.
What accelerated approval means
The accelerated approval pathway can allow earlier access for serious conditions based on a surrogate or intermediate endpoint that is considered reasonably likely to predict clinical benefit. The manufacturer must conduct post-approval studies to verify the anticipated benefit. The pathway is still an FDA approval, with ongoing confirmatory requirements. Forzinity is a prescription medicine and carries product-specific risks and instructions. Patients and caregivers should use the FDA-approved labeling and speak with the treating specialist about eligibility, expected benefits, monitoring and access.
Why this matters in peptide medicine
Forzinity is an example of a peptide-based medicine with a defined, narrow FDA-approved indication. The approval is not evidence that other peptides sold online, compounded versions, or products labeled “research use only” are reviewed or safe for people.
Sources & references
A chemical record identifies a reference, a study reports a defined investigation, and a product label concerns a specific medicine. A supplier catalogue is not clinical evidence.
General education, not personal medical advice. Ask an appropriately qualified professional about a medicine, symptom or treatment question.